Scarica l'app Stockscreener
13.15
0.98%
-0.13
Dopo l'orario di chiusura:
13.96
0.81
+6.16%
Precedente Chiudi:
$13.28
Aprire:
$13.35
Volume 24 ore:
212.25K
Relative Volume:
0.76
Capitalizzazione di mercato:
$433.60M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-10.35
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
-0.53%
1M Prestazione:
+12.49%
6M Prestazione:
+16.58%
1 anno Prestazione:
+100.76%
Intervallo 1D:
$12.87
$13.84
Intervallo di 1 settimana:
$12.43
$13.91
Portata 52W:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.15 | 433.60M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
NeuroPace secures USD 75M in debt financing - Medical Buyer
BNP Paribas Financial Markets Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NeuroPace Secures $75 Million Credit Facility with MidCap - TipRanks
NeuroPace Secures $75 Million Credit Facility From MidCap Financial - marketscreener.com
NeuroPace secures $75 million credit facility with MidCap Financial - Investing.com Australia
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Neuropace IncEnters Into Credit Agreement With Midcap Funding Iv Trust - marketscreener.com
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives - Nasdaq
NeuroPace secures $75 million credit facility with MidCap Financial By Investing.com - Investing.com UK
NeuroPace Secures Up to $75 Million in Debt Financing - TradingView
$75M Financing Fuels NeuroPace's Epilepsy Treatment Expansion: 5 Key Growth Initiatives Revealed - Stock Titan
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
FY2028 EPS Estimates for NeuroPace Cut by Leerink Partnrs - MarketBeat
Research Analysts Set Expectations for NeuroPace Q3 Earnings - MarketBeat
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
Cantor Fitzgerald maintains overweight rating on NeuroPace stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains overweight rating on NeuroPace stock - Investing.com
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - PR Newswire
NeuroPace, Inc. (NASDAQ:NPCE) Shares Sold by Millennium Management LLC - MarketBeat
Q2 Earnings Estimate for NeuroPace Issued By HC Wainwright - MarketBeat
Brokerages Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $15.50 - Defense World
Q2 Earnings Forecast for NeuroPace Issued By HC Wainwright - Defense World
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Northern Trust Corp - MarketBeat
FY2028 EPS Estimates for NeuroPace Decreased by Analyst - Defense World
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Point72 Asset Management L.P. Takes $369,000 Position in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace (NASDAQ:NPCE) Now Covered by HC Wainwright - Defense World
NeuroPace falls after setback in trial for neuromodulation system - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) Initiates Coverage with "Buy" Rating by HC Wain - GuruFocus
H.C. Wainwright sets $18 target on NeuroPace stock with Buy rating - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Eagle-Tribune
NeuroPace Inc (NPCE) Shares Gap Down to $11.75 on May 28 - GuruFocus
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial - Yahoo Finance
NeuroPace reports initial one-year outcomes from trial of RNS System - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - Nasdaq
Analyst Expectations For NeuroPace's Future - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates NeuroPace at Buy With $18 Price Target - marketscreener.com
Transcript : NeuroPace, Inc.Special Call - marketscreener.com
NeuroPace (NPCE) Receives Positive Initiation from H.C. Wainwrig - GuruFocus
NeuroPace (NPCE) Shares NAUTILUS Study Results on RNS System | N - GuruFocus
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):